Floatz logo

Spartalizumab

In Expansion: Melanoma, Non-small Cell Lung Cancer

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the In Expansion: Melanoma, Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
niz985
Novartis Pharmaceuticals
Phase 1CC
Tislelizumab
Novartis Pharmaceuticals
Phase 1CC
Pyrotinib
Novartis Pharmaceuticals
Phase 1CC
rc48-adc
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Spartalizumab is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →